{"id":"gp2017-adalimumab","safety":{"commonSideEffects":[{"rate":"10–15%","effect":"Injection site reactions"},{"rate":"10–20%","effect":"Upper respiratory tract infections"},{"rate":"5–10%","effect":"Headache"},{"rate":"1–3%","effect":"Serious infections (tuberculosis, opportunistic infections)"},{"rate":"low, consistent with TNF inhibitor class","effect":"Malignancy risk"}]},"_chembl":{"chemblId":"CHEMBL1201580","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As an adalimumab biosimilar, GP2017 is a fully human monoclonal antibody that binds to and neutralizes TNF-α, a key pro-inflammatory cytokine. By inhibiting TNF-α signaling, it suppresses the inflammatory cascade underlying autoimmune and inflammatory conditions. This mechanism is identical to the reference adalimumab product.","oneSentence":"GP2017 is a biosimilar of adalimumab that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation and immune-mediated disease activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:14:09.803Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"},{"name":"Psoriasis"},{"name":"Ankylosing spondylitis"},{"name":"Other TNF-α-mediated inflammatory conditions"}]},"trialDetails":[{"nctId":"NCT03259074","phase":"PHASE3","title":"Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-11-30","conditions":"Ankylosing Spondylitis","enrollment":859},{"nctId":"NCT02744755","phase":"PHASE3","title":"Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Sandoz","startDate":"2016-03-31","conditions":"Rheumatoid Arthritis","enrollment":353},{"nctId":"NCT02016105","phase":"PHASE3","title":"Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira","status":"COMPLETED","sponsor":"Sandoz","startDate":"2013-12","conditions":"Plaque Type Psoriasis","enrollment":465}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":47,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GP2017 Adalimumab","genericName":"GP2017 Adalimumab","companyName":"Sandoz","companyId":"sandoz","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GP2017 Adalimumab is a biosimilar of Humira, an antibody that inhibits tumor necrosis factor, a protein involved in inflammation. It has been studied in clinical trials for the treatment of plaque type psoriasis, ankylosing spondylitis, and rheumatoid arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}